{
  "id": 760227,
  "title": "Guggenheim raises Erasca stock price target to $21 on pipeline progress",
  "url": "https://urgent.news/2026/08/13/guggenheim-raises-erasca-stock-price-target-to-21-on-pipeline-progress",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-13T11:32:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/guggenheim-raises-erasca-stock-price-target-to-21-on-pipeline-progress-93CH-4857504"
  },
  "original_language": "en",
  "account": "Guggenheim upgraded its price target on Erasca Inc (NASDAQ:ERAS) stock to $21 from $20 on Wednesday, retaining a Buy rating. The current stock price stands at $18.58, with targets ranging from $18 to $30. Over the past year, shares have surged more than 1,000%, showcasing growing investor confidence in the company's RAS inhibitor pipeline. Erasca's second-quarter 2026 results and pipeline update were recently disclosed. The firm presented updated Phase 1 AURORAS-1 study data for ERAS-0015, a pan-RAS inhibitor, both as monotherapy and in combination with panitumumab. Management revealed plans to prioritize advancing ERAS-0015 development in non-small cell lung cancer and first-line pancreatic ductal adenocarcinoma towards potential pivotal study initiations in 2027. Erasca also announced a Phase 1 clinical collaboration with Merck to assess an ERAS-0015 plus pembrolizumab combination in RAS-mutant solid tumors, to be run by Erasca. The company raised $500 million in equity in July, ending the quarter with $409 million in cash and equivalents. With a strong current ratio of 8.29, Erasca's liquid assets far exceed short-term obligations. However, InvestingPro analysis indicates the stock may be overvalued at its current price relative to its Fair Value estimate. Guggenheim projects first clinical data from Erasca's other program, ERAS-4001, a pan-KRAS inhibitor, in solid tumors in the second half of 2026. Additionally, Erasca recently completed a public stock offering, raising approximately $632.5 million by selling 36.1 million shares at $17.50 per share. Analysts from H.C. Wainwright and Jefferies have also raised their price targets for Erasca, citing progress in the ERAS-0015 program and strong trial data.",
  "summary": "Guggenheim has raised its price target on Erasca Inc (NASDAQ:ERAS) stock to $21 from $20, maintaining a Buy rating on the shares. The biotech company has reported progress in its RAS inhibitor pipeline, with data from the ongoing Phase 1 AURORAS-1 study of ERAS-0015, a pan-RAS inhibitor, showing promising results. Erasca recently announced plans to prioritize advancing development of ERAS-0015 in non-small cell lung cancer and first-line pancreatic ductal adenocarcinoma toward potential pivotal study initiations starting in 2027. The company completed a $500 million equity raise in July, and ended the second quarter with $409 million in cash and equivalents. Analysts from H.C. Wainwright and Jefferies have also raised their price targets for Erasca, citing strong trial data and the drug's potential best-in-class pan-RAS profile.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Guggenheim cuts Cava stock price target on margin pressures",
        "url": "https://urgent.news/2026/08/13/guggenheim-cuts-cava-stock-price-target-on-margin-pressures",
        "published": "2026-08-13T11:32:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}